Shots:
- Grifols acquires the remaining 56% share of GigaGen for $80M. The acquisition will add GigaGen’s pipeline of recombinant polyclonal Abs, including GIGA-2050 and boost Grifol’s portfolio if I-O therapies
- Earlier, in 2017, Grifols acquired a 44% stake in GigaGen, when the two companies collaborated to develop polyclonal antibodies under a $50M pact
- GIGA-2050 is expected to be evaluated in P- I trial in the US in spring 2021, following the IND approval
Click here to read full press release/ article | Ref: PRNewswire | Image: Yicai Global
The post Grifols Acquires Remaining 56% of GigaGen for ~$80M first appeared on PharmaShots.
